A group of medical advisors have told U.S. regulators that the world's best-selling prescription arthritis drug, Celebrex, should stay on the market but with a warning about side-effects.
The discussion follows a study in December that showed Celebrex raises the risk of heart problems for some patients.
But the advisory group decided that the benefits of the drug outweigh the potential harm.
The panel also said that another drug from the Pfizer company, Bextra, also raises heart concerns but should also stay on the market.
Pfizer sold $3.3 billion worth of Celebrex last year.
The U.S. Food and Drug Administration will make a final decision on the future of the drug, but the regulators generally follow suggestions from their scientific advisors.
Some information for this report provided by AP, Bloomberg and Reuters.